Truist raised the firm’s price target on UnitedHealth to $640 from $610 and keeps a Buy rating on the shares as part of a broader research note and outlook for FY24 among Healthcare Services names. Truist remains “broadly constructive” on core fundamentals across the group given “brisk sector tailwinds” around demand, the move to value-based care, and demographics, along with the group’s attractive positioning within segments and robust cash generation. The firm also notes that financial flexibility across much of the group should continue to underpin strong growth investment, M&A, and shareholder value creation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UNH:
- M & A News: UnitedHealth (NYSE:UNH) Agrees to Divest Its Brazilian Operations
- UnitedHealth confirms FY24 adjusted earnings outlook
- UnitedHealth to sell operations in Brazil, expects to record $7B charge
- UnitedHealth said to use secret rules to restrict rehab care, STAT reports
- Snap upgraded, Roku downgraded: Wall Street’s top analyst calls